CD8A and cancer: This can be carried out sequentially: aiming at targeting, firstly, CAFs (such as targeting ECM remodeling to remove the barrier for CD8+ T-cell infiltration) and, secondly, cancer cells (such as performing PD-1/PD-L1 immune checkpoint therapy).